1. ALLA AKTIER
  2. NYHETER
  3. MEDIVIR

Medivir

Nyheter Medivir Nyheter alla bolag

Medivir to present at the Redeye Fight Cancer Event

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Redeye Fight Cancer Event, today January 22, 2025.

CEO Jens Lindberg will present the company and data from the recently finalized phase 1b/2a clinical study with fostroxacitabine bralpamide (fostrox) at 14.38 CET.

The presentation is live broadcasted and can be followed at the event page;
https://www.redeye.se/events/1052608/redeye-theme-fight-cancer-3
The presentation will be available after the meeting on Medivirs website; www.medivir.com. 

For additional information, please contact;
Magnus Christensen, CFO, Medivir AB
Telephone: +46 8 5468 3100
E-mail: magnus.christensen@medivir.com

About Medivir
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a drug candidate designed to selectively treat cancer cells in the liver and to minimize side effects. Collaborations and partnerships are important parts of Medivir’s business model, and the drug development is conducted either by Medivir or in partnership. Medivir’s share (ticker: MVIR) is listed on Nasdaq Stockholm’s Small Cap list. www.medivir.com. 

Attachments
Press Release (PDF)

Datum 2025-01-22, kl 12:00
Källa MFN
Bifogade filer
Press Release (PDF)
Hej Serverägare! Har du problem med troll och spam? Nu finns möjligheten att sätta en liten avgift, t.ex. 20kr, på discord invites och därmed stoppa många återkommande troll samtidigt som du tjänar lite pengar. Kolla in Invite Paywall.